SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-25.1M $-30.0M $-32.6M $-4.2M $-30.5M
Depreciation & Amortization — — — — —
Depreciation $41.0K $26.0K $447.0K $1.2M $1.3M
Amortization — — — — —
Stock-Based Compensation — — — — —
Net Cash from Operating Activities $-24.6M $-29.4M $-24.5M $-9.5M $-4.3M
Investing Activities
Capital Expenditures $2.0K $27.0K $589.0K $704.0K $431.0K
Business Acquisitions — — — — —
Net Cash from Investing Activities $-9.6M $-22.5M $1.6M $-488.0K —
Financing Activities
Dividends Paid — — — — —
Stock Repurchases — — — — —
Net Cash from Financing Activities $10.0M $40.5M $37.7M $40.8M —
Net Change in Cash $-24.2M $-11.3M $14.7M $30.8M $-983.0K
Free Cash Flow $-24.6M $-29.4M $-25.1M $-10.2M $-4.7M
← Newer Page 2 of 2 Older →